Clinical significance of Helicobacter pylori in pathogenesis of idiopathic thrombocytopenic purpura.
- Author:
Rong KONG
1
;
Hong-Chun QIU
;
Peng-Fei WU
;
Xue-Hua NIU
;
Wen-Xiang SHEN
;
Yong WANG
Author Information
1. Department of Hematology, Kunshan Third People Hospital, Kunshan 215300, Jiangsu Province, China. kongrong1963@sina.com
- Publication Type:Journal Article
- MeSH:
Adult;
Anti-Bacterial Agents;
therapeutic use;
Case-Control Studies;
Combined Modality Therapy;
Female;
Glucocorticoids;
therapeutic use;
Helicobacter Infections;
complications;
drug therapy;
Helicobacter pylori;
Humans;
Male;
Platelet Count;
Purpura, Thrombocytopenic, Idiopathic;
complications;
drug therapy;
microbiology
- From:
Journal of Experimental Hematology
2008;16(5):1222-1226
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the infection incidence of Helicobacter pylori (HP) in patients with idiopathic thrombocytopenic purpura (ITP) and curative efficacy of glucocorticoids combined with anti-helicobacter. 100 ITP patients with positive HP were divided randomly into 3 groups: glucocorticoid group (treatment with glucocorticoids, n = 35), anti-HP treatment group (HP eradication, n = 30) and combined treatment group (glucocorticoid combined with HP eradication, n = 35). 100 healthy individuals were selected as control. The results showed that HP infection rate in ITP group was 70%, while HP infection rate in control group (persons received physical examination) was 56%, there was significant difference between two groups (p < 0.05). The HP of 31 cases in combined treatment group was eradicated that the platelet count in 23 out of 31 cases recovered to normal, and in 8 cases was higher than that before treatment, which mean count was (165 +/- 225) x 10(9)/L, this value had statistical significance as compared with that before treatment (p < 0.01). Total efficiency in this group reached to 89%, and relapse rate within 1 year was 8%. The HP infection of 2 cases in glucocorticoid group had been turned to negative naturally, and platelet count recovered to normal, while HP infection in remained 33 cases was still positive. The platelet count in 23 out of 33 cases of that group was not back to normal, but back to normal in 10 cases. The platelet mean count in that group was (78 +/- 26) x 10(9)/L with total efficiency rate of 68% and relapse rate within 1 year was 37%. In the anti-HP treatment group, HP infection in 25 cases was eradicated and platelet count in 9 out of 25 cases recovered to normal, that platelet count in 9 cases was higher than that before treatment, platelet mean count was (135 +/- 174) x 10(9)/L), there was significant difference (p < 0.01), as compared with value before treatment. Total efficiency rate in this group reached to 60%, and relapse rate within 1 year was 33%. It is concluded that the patients with ITP have higher HP infection incidence, and the eradication of HP is effective therapy for the ITP patients with HP infection, which can be used as initial treatment.
